Endocare and Former CEO Paul W. Mikus Agree to Terminate Indemnification Agreement

Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that it has entered into an agreement with its former CEO Paul W. Mikus that terminates Mr. Mikus' indemnification agreement in exchange for Endocare's waiver of certain severance and legal fee reimbursement rights. As a result of this new agreement, Endocare is no longer obligated to pay any future legal costs for Mr. Mikus.

Endocare CFO Michael R. Rodriguez said, "This agreement brings to a close our indemnification of former management and a long, expensive chapter for Endocare. It finally and immediately ends what has been a significant expense and allows management to focus more completely on building our business."

Endocare had previously announced a similar agreement with its former CFO. For more information regarding the agreement with Mr. Mikus, please see the related Form 8-K filed by Endocare today with the Securities and Exchange Commission.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

     Investor Contact:                 Media Contact:
     Matt Clawson                      Len Hall
     Allen & Caron, Inc.               Allen & Caron, Inc.
     (949) 474-4300                    (949) 474-4300
     This email address is being protected from spambots. You need JavaScript enabled to view it.               This email address is being protected from spambots. You need JavaScript enabled to view it.
     http://www.allencaron.com         http://www.allencaron.com

     For Additional Information:
     Terrence A. Noonan, Interim CEO
     Michael R. Rodriguez, CFO
     Endocare, Inc.
     (949) 450-5400
     http://www.endocare.com

SOURCE Endocare, Inc.